Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSISET psilocybin setting trial in depression
2025-522961-31-00Phase 2Withdrawn
- Sponsor
- University of Copenhagen
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of psilocybin in major depressive disorder (MDD) (2 arms), sponsored by University of Copenhagen. Primary endpoint: Change in depressive symptoms by MADRS. Planned start Mar 2026; status: withdrawn.
02
Drugs
psilocybin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2025-522961-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522961-31-00.